Multiple myeloma is a cancer of plasma cells, the cells in the bone marrow responsible for producing antibodies. The way it is diagnosed reflects the complexity of a condition that can present in multiple ways, affect several organ systems, and look different on different tests depending on which aspect of the disease is being evaluated. A diagnosis of multiple myeloma does not come from a single test. It comes from a pattern of findings across several investigations that together build a picture consistent with the condition.
Understanding how the diagnostic process is structured helps patients and families make sense of what is being ordered and why, and it helps contextualize results that might otherwise seem disconnected from each other.
Initial Presentation and Why It Varies
Multiple myeloma is sometimes detected incidentally, when a blood test ordered for a different reason returns abnormal results that prompt further investigation. In other cases, a patient presents with symptoms that lead a doctor to suspect the diagnosis, including bone pain particularly in the back or ribs, fatigue associated with anemia, recurrent infections, or kidney function changes. The variety of presenting symptoms reflects the fact that the disease affects the body through several mechanisms simultaneously, through the overproduction of abnormal protein, through the displacement of normal marrow cells, and through the effects on bones and kidneys.
This variability in presentation means that the initial workup is often broader than a targeted test for a single marker. A blood count that shows anemia, a biochemical panel that shows elevated calcium or abnormal kidney function, and a protein electrophoresis that identifies an abnormal immunoglobulin band are often the combination of findings that together raise the suspicion of a plasma cell disorder.
The Diagnostic Investigations That Follow
Once a plasma cell disorder is suspected, the investigation moves toward confirming the diagnosis and characterizing the disease. Serum protein electrophoresis and immunofixation identify and characterize the abnormal protein produced by the myeloma cells, known as the M protein or paraprotein. The level of this protein provides information about the disease burden and is used in monitoring over time as well as in diagnosis.
A bone marrow biopsy is the investigation that provides the most definitive diagnostic information, because it allows direct examination of the proportion of plasma cells in the marrow and assessment of their characteristics. A plasma cell percentage above ten percent in the marrow, in combination with evidence of organ damage attributable to the plasma cell disorder, is part of the diagnostic criteria for active myeloma requiring treatment. Below that threshold, the finding may represent a precursor condition that requires monitoring rather than immediate treatment.
Imaging studies, including low-dose whole-body CT and in some cases MRI or PET-CT, are used to assess for bone lesions and to evaluate disease extent. The imaging findings contribute to the diagnostic picture and also help guide treatment decisions by identifying areas of skeletal involvement.
Medgenome’s oncology diagnostics cover the laboratory investigations that form part of the multiple myeloma diagnostic pathway, including protein studies, bone marrow analysis support, and molecular testing. The specific tests available and how they contribute to the diagnostic workup are outlined through this page on the multiple myeloma test options, which provides the clinical context for each investigation alongside the practical ordering information.
The molecular characterization of multiple myeloma through cytogenetic and FISH testing of bone marrow samples is increasingly important not only for diagnosis but for treatment planning, because certain chromosomal abnormalities in the myeloma cells are associated with different prognosis and response to different treatment approaches. This testing is typically done at diagnosis and guides the choice of initial treatment regimen.
Staging and What It Means for Treatment
Once the diagnosis is confirmed, staging provides a framework for understanding disease severity and guiding treatment decisions. The Revised International Staging System uses a combination of serum albumin, beta-2 microglobulin, lactate dehydrogenase, and the presence of high-risk cytogenetic features to classify myeloma into three stages with different prognostic implications. This staging, combined with the patient’s overall health and treatment goals, forms the basis of the treatment conversation that follows diagnosis.
